Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q3 2022 · 10-Q
Revenue$15.74M$15.74M−89.9% vs Q3 2021 Net Income-$91.65M-$91.65MN/M vs Q3 2021 EPS Diluted-$0.98-$0.98N/M vs Q3 2021 Operating Income-$93,657,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$52,745,000N/M Margins · derivedOperating margin-595.2%−627.9 pt vs Q3 2021
Net margin-582.5%−614.4 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 7, 2022 · 38 d after period end